Phase I study of BAY 94‐9027, a PEG ylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia A-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I study of BAY 94‐9027, a PEG ylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia A

Published:2014-04 Issue:4 Volume:12 Page:488-496
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Coyle T. E.¹,Reding M. T.²,Lin J. C.³,Michaels L. A.⁴,Shah A.⁴,Powell J.⁵

Affiliation:

1. Upstate Medical University State University of New York Syracuse NYUSA

2. University of Minnesota Medical Center Minneapolis MNUSA

3. Brigham and Women's Hospital Boston MAUSA

4. Bayer HealthCare Pharmaceuticals Whippany NJUSA

5. University of California Davis Sacramento CA USA

Funder

Bayer Healthcare

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.12506

Reference27 articles.

1. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs

2. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

3. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

4. Guidelines for the management of hemophilia

5. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review;Drugs in R&D;2024-08-20

2. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII;Acta Haematologica;2024-04-23

3. Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review;Haemophilia;2024-03-29

4. Variability in combinations of APTT reagent and substrate plasma for a one‐stage clotting assay to measure factor VIII products;International Journal of Laboratory Hematology;2024-03

5. A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A;European Journal of Haematology;2024-01-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3